<DOC>
	<DOCNO>NCT01063439</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity busulfan , etoposide , cytarabine melphalan ( BuEAM ) include intravenous busulfan instead BCNU standard BEAM conditioning autologous stem cell transplantation patient NHL .</brief_summary>
	<brief_title>BuEAM Conditioning Autologous Stem Cell Transplantation ( ASCT ) Treat Diffuse Large B Cell Lymphoma ( DLCBL )</brief_title>
	<detailed_description>Among high-dose conditioning regimen commonly use patient NHL BEAM ( BCNU , etoposide , cytarabine , melphalan ) , BEAC ( BCNU , etoposide , cytarabine , cyclophosphamide ) , CBV ( cyclophosphamide , carmustine , etoposide ) , combination regimen total body irradiation . Three-year progression free survival patient NHL receive high-dose chemotherapy follow autologous stem cell rescue report 40-50 % , still unsatisfactory . Busulfan ( Bu ) -based preparative regimen , commonly use allogeneic SCT also study ASCT lymphoma . The development intravenous busulfan achieve 100 % bioavailability bypass oral route increase safety reliability generate therapeutic busulfan level , maximize efficacy . Recently , one prospective study show combination condition regimen i.v . busulfan , cyclophosphamide , etoposide find well tolerate seem effective patient aggressive NHL . Another prospective study multiple myeloma patient show i.v . busulfan melphalan condition regimen make grade 3-4 non-hematological complication .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients highintermediate/high risk international prognostic index diagnosis salvage chemotherapysensitive relapse/refractory non Hodgkin 's lymphoma Patients histologically confirm diffuse large B cell lymphoma diagnosis Patients treat rituximab base regimen previously Patients receive therapy highdose chemotherapy stem cell transplantation Life expectation least 3 month ECOG performance status ≤ 2 ( See Appendix II ) Adequate hepatic function ( serum bilirubin le 2.0 mg/dL , AST ALT less three time upper normal limit ) Adequate renal function ( serum creatinine le 2.0 mg/dL ) . Adequate cardiac function ( ejection fraction ≥ 45 % MUGA scan echocardiogram ) . Adequate bone marrow function ( ANC ≥ 1,000/mm3 platelet count ≥ 75,000/mm3 ) . All patient fully informed nature purpose study inform consent give start treatment . All patient fully understand right trial abandon without disadvantage Patients central nervous system involvement lymphoma Patients positive human immunodeficiency virus Pregnant breast feed woman Young woman without pregnancy test prior treatment pregnancy test reveals positive . Young woman without reliable proper contraceptive method Man willing contraception Concurrent history neoplasm NHL life expectancy le 3 month ( except curatively treat nonmelanoma skin cancer insitu uterine cervix cancer ) . History clinically significant cardiac dysfunction ( e.g . congestive heart failure , symptomatic coronary artery disease , medically uncontrolled arrhythmia ) myocardial infarction within 12 month A psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible . Significant infection uncontrolled bleed Enrollment clinical trial within 4 week prior treatment Any preexist medical condition sufficient severity prevent full compliance study Patient willing unable obey study protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>NHL</keyword>
</DOC>